Table 1.
Characterization of cases and controls before and after adjustment.
| MRONJ Group | Controls Group | p-Value | MRONJ Group | Controls Group | p-Value | |
|---|---|---|---|---|---|---|
| N = 75 (%) | N = 171 (%) | N = 75 | N = 75 | |||
| (After Adjustment) | (After Adjustment) | |||||
| Age-Mean (SD) | 68.3 (9.7) | 60.5 (12.7) | < 0.001 | 68.3 (9.7) | 68.8 (10.3) | 0.757 |
| Sex | ||||||
| Male | 30 (40.0) | 34 (19.9) | 0.002 | 30 (40.0) | 22 (29.3) | 0.230 |
| Female | 45 (60.0) | 137 (80.1) | 45 (60.0) | 53 (70.7) | ||
| Primary cancer type | ||||||
| Multiple myeloma | 14 (18.7) | 11 (6.4) | 0.007 | 14 (18.7) | 9 (12.0) | 0.365 |
| Metastatic breast cancer | 38 (50.7) | 128 (74.9) | <0.001 | 38 (50.7) | 46 (61.3) | 0.250 |
| Metastatic prostate cancer | 20 (26.7) | 20 (11.7) | 0.006 | 20 (26.7) | 13 (17.3) | 0.237 |
| Metastatic lung cancer | 3 (4.0) | 12 (7.0) | 0.535 | 3 (4.0) | 7 (9.3) | 0.326 |
| Bone metastasis treatment drugs | ||||||
| Denosumab | 20 (26.7) | 27 (15.8) | 0.069 | 20 (26.7) | 11 (14.7) | 0.107 |
| Zoledronic acid | 55 (73.3) | 144 (84.2) | 0.069 | 55 (73.3) | 64 (85.3) | 0.107 |
| Mean number of doses administered (SD) | 23.5 (15.7) | 18.3 (12.6) | 0.006 | 23.5 (15.7) | 16.91 (12.6) | 0.005 |
| Cancer medications | ||||||
| Chemotherapy | 42 (56.0) | 144 (84.2) | <0.001 | 42 (56.0) | 60 (80.0) | 0.003 |
| Hormonal therapy | 38 (50.7) | 116 (67.8) | 0.016 | 38 (50.7) | 47 (62.7) | 0.187 |
| Novel molecules | 21 (28.0) | 70 (40.9) | 0.073 | 21 (28.0) | 23 (30.7) | 0.858 |
Legend: MRONJ = medication-related osteonecrosis of the jaws; SD = standard deviation.